{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:27:09Z","timestamp":1793986029422,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.eprac.2026.10.009","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:13:14Z","timestamp":1792739594000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Denosumab Biosimilars Versus Denosumab in Postmenopausal Osteoporosis: Updated Systematic Review and Meta-Analysis of Randomized Trials"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-4966","authenticated-orcid":false,"given":"Ashima","family":"Mittal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Miao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele Denti","family":"De Geroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Zeghbi","family":"Cochenski Borba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.10.009_bib1","unstructured":"Kanis JA; World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. University of Sheffield, World Health Organization Collaborating Centre for Metabolic Bone Diseases; 2007."},{"issue":"21","key":"10.1016\/j.eprac.2026.10.009_bib2","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMcp2307353","article-title":"Postmenopausal osteoporosis","volume":"389","author":"Walker","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2026.10.009_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.10.009_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107224","article-title":"Biosimilars and interchangeability: Regulatory, scientific, and global perspectives","volume":"213","author":"Iskit","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.eprac.2026.10.009_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00393-025-01737-6","article-title":"Comparative efficacy and safety of denosumab biosimilar and originator in postmenopausal osteoporosis: a meta-analysis of randomized controlled trials","volume":"85","author":"Lee","year":"2026","journal-title":"Z Rheumatol"},{"issue":"1","key":"10.1016\/j.eprac.2026.10.009_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10238-026-02070-1","article-title":"Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials","volume":"26","author":"Shakibaei","year":"2026","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.eprac.2026.10.009_bib7","unstructured":"Higgins JPT, Thomas J, Chandler J, et al, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3. Cochrane; 2022. Accessed April 20, 2024. www.training.cochrane.org\/handbook"},{"key":"10.1016\/j.eprac.2026.10.009_bib8","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.10.009_bib9","unstructured":"A phase 3 study to compare biosimilar denosumab with Prolia. ClinicalTrials.gov identifier: NCT05405725. Enzene Biosciences Ltd. Updated February 10, 2026. Accessed July 13, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05405725"},{"key":"10.1016\/j.eprac.2026.10.009_bib10","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published November 27, 2017. Accessed October 3, 2026. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm"},{"key":"10.1016\/j.eprac.2026.10.009_bib11","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.eprac.2026.10.009_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.10.009_bib13","article-title":"Copenhagen Trial Unit, Centre for Clinical Intervention Research","year":"2016","journal-title":"Rigshospitalet"},{"issue":"2","key":"10.1016\/j.eprac.2026.10.009_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s12020-025-04430-5","article-title":"Efficacy and safety of denosumab biosimilar CMAB807 versus Prolia in Chinese postmenopausal women with osteoporosis","volume":"90","author":"Jiang","year":"2025","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.eprac.2026.10.009_bib15","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00198-025-07711-x","article-title":"A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis","volume":"36","author":"Seefried","year":"2025","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2026.10.009_bib16","article-title":"Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study","volume":"29","author":"Zhu","year":"2026","journal-title":"Bone Rep"},{"issue":"3","key":"10.1016\/j.eprac.2026.10.009_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/pharmaceutics18030291","article-title":"Phase III study to confirm clinical similarity of MB09, a denosumab biosimilar, and Prolia in postmenopausal women with osteoporosis (SIMBA study)","volume":"18","author":"Supronik","year":"2026","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.eprac.2026.10.009_bib18","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf164","article-title":"LUMIADE 3: Therapeutic equivalence of denosumab biosimilar FKS518 to reference product in postmenopausal osteoporosis","volume":"9","author":"Krecipro-Nizinska","year":"2025","journal-title":"J Endocr Soc"},{"issue":"8","key":"10.1016\/j.eprac.2026.10.009_bib19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/14712598.2025.2538609","article-title":"A randomized, double blind, parallel design, repeat dose, 2-arm, multicenter study comparing the efficacy, safety, immunogenicity, and pharmacokinetic profiles of a denosumab biosimilar, AVT03, in postmenopausal women with osteoporosis","volume":"25","author":"Lortkipanidze","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2026.10.009_bib20","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis","volume":"35","author":"Reginster","year":"2024","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.1016\/j.eprac.2026.10.009_bib21","doi-asserted-by":"crossref","first-page":"e1951","DOI":"10.1210\/clinem\/dgae611","article-title":"Proposed denosumab biosimilar SB16 vs reference denosumab in postmenopausal osteoporosis: Phase 3 results up to month 12","volume":"110","author":"Langdahl","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2026.10.009_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2026.10.009_bib23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/ijp.IJP_346_19","article-title":"Denosumab biosimilar in postmenopausal osteoporotic women: A randomized, assessor-blind, active-controlled clinical trial","volume":"53","author":"Singh","year":"2021","journal-title":"Indian J Pharmacol"},{"issue":"1","key":"10.1016\/j.eprac.2026.10.009_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13075-022-02840-8","article-title":"Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial","volume":"24","author":"Jamshidi","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.eprac.2026.10.009_bib25","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.59556\/japi.73.0772","article-title":"A prospective, active-controlled, randomized, double-blind, multicenter, phase III study to compare the safety and efficacy of biosimilar denosumab vs reference denosumab in the treatment of postmenopausal osteoporosis","volume":"73","author":"Paul","year":"2025","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"10.1016\/j.eprac.2026.10.009_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziag062","article-title":"Efficacy, pharmacodynamics, pharmacokinetics, safety, and immunogenicity of Bmab 1000 vs reference denosumab: 78-wk results from a randomized, double-blind, multicenter, parallel-arm Phase 3 trial (DEVOTE) in women with postmenopausal osteoporosis","volume":"10","author":"Eastell","year":"2026","journal-title":"JBMR Plus"},{"issue":"2","key":"10.1016\/j.eprac.2026.10.009_bib27","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.eprac.2026.10.009_bib28","unstructured":"Reginster J, Silverman S, Czerwinski E, et al. Efficacy and safety results of CT-P41 (proposed denosumab biosimilar) compared to reference denosumab in postmenopausal women with osteoporosis: 78-week results from phase 3 randomized controlled trial. Presented at: ACR Convergence 2024; November 14-19, 2024; Washington, DC. Abstract 2563."},{"issue":"5","key":"10.1016\/j.eprac.2026.10.009_bib29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00198-026-07964-0","article-title":"Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase","volume":"37","author":"Ferrari","year":"2026","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2026.10.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117371","article-title":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","volume":"192","author":"Chung","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2026.10.009_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jot.2022.06.007","article-title":"Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study","volume":"38","author":"Gu","year":"2022","journal-title":"J Orthop Translat"},{"issue":"7","key":"10.1016\/j.eprac.2026.10.009_bib32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/14712598.2024.2352587","article-title":"Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis","volume":"24","author":"Jiang","year":"2024","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2026.10.009_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J Clin Densitom"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26012929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:11:46Z","timestamp":1793985106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26012929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S1530891X26012929"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.10.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Denosumab Biosimilars Versus Denosumab in Postmenopausal Osteoporosis: Updated Systematic Review and Meta-Analysis of Randomized Trials","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}